Drugs / S. sonnei 1790GAHB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02034500 | Mar 2014 → Apr 2015 | shigellosis | GSK Vaccines Institute For Global Health S.r.l. | Completed | No outcome recorded |
| Phase 1 | NCT02017899 | Feb 2014 → Mar 2015 | shigellosis | GSK Vaccines Institute For Global Health S.r.l. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S. sonnei 1790GAHB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02034500 ↗ |
| Known as | 1790GAHB | “The single-component candidate vaccine against Shigella sonnei (1790GAHB), developed using the GMMA technology, contains the O antigen (OAg) portion of lipopolysaccharide (LPS)...” PMID 34017343 ↗ May 2021 |
| Modality | Vaccine | “candidate Shigella sonnei vaccine (1790GAHB) using the Generalized Modules for Membrane Antigens (GMMA) technology” PMID 28735965 ↗ Jul 2017 |
| Route | Intramuscular | “administered by intramuscular route” NCT02017899 ↗ |